Dividend yield of Supernus Pharmaceuticals, Inc.
The dividend yield or dividend-price ratio of a share is the dividend per share, divided by the price per share. It is also a company's total annual dividend payments divided by its market capitalization, assuming the number of shares is constant, and is often expressed as a percentage. The reciprocal of the dividend yield is the price-dividend ratio.
A higher dividend yield has been considered to be desirable among many investors. A high dividend yield can be considered to be evidence that a stock is underpriced or that the company has fallen on hard times and future dividends will not be as high as previous ones. Similarly a low dividend yield can be considered evidence that the stock is overpriced or that future dividends might be higher. Some investors may find a higher dividend yield attractive, for instance as an aid to marketing a fund to retail investors, or maybe because they cannot get their hands on the capital, which may be tied up in a trust arrangement. In contrast some investors may find a higher dividend yield unattractive, perhaps because it increases their tax bill.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
|Company||Industry||Return on equity|
|PX Praxair, Inc.||NYSE > Basic Industries > Major Chemicals||27.08%|
|MXIM Maxim Integrated Products, Inc.||NASDAQ > Technology > Semiconductors||27.17%|
|TPIC TPI Composites, Inc.||NASDAQ > Energy > Industrial Machinery/Components||27.18%|
|TSEM Tower Semiconductor Ltd.||NASDAQ > Technology > Semiconductors||27.19%|
|NMRK Newmark Group, Inc.||NASDAQ||27.19%|
|TEP Tallgrass Energy Partners, LP||NYSE > Public Utilities > Natural Gas Distribution||27.22%|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||27.27%|
|OPNT Opiant Pharmaceuticals, Inc.||NASDAQ > Basic Industries > Precious Metals||2,031.11%|
|PBT Permian Basin Royalty Trust||NYSE > Energy > Oil & Gas Production||4,888.60%|
|IDXX IDEXX Laboratories, Inc.||NASDAQ > Health Care > Biotechnology: In Vitro & In Vivo Diagnostic Substances||8,410.92%|
|NRT North European Oil Royality Trust||NYSE > Energy > Oil & Gas Production||8,437.44%|
|CQH Cheniere Energy Partners LP Holdings, LLC||NYSEMKT > Public Utilities > Oil/Gas Transmission||9,523.81%|
|BPT BP Prudhoe Bay Royalty Trust||NYSE > Energy > Integrated oil Companies||9,929.09%|